ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO Recommends Discussing Pharmacological Prevention

July 26, 2013

House Committee Expands Rauscher Pay Bill, Includes All NIH Directors, Asst. Secretary

July 30, 1976

In Brief: Cancer Series Helps Do In Woodward As Post Metro Editor; OCC RFP Canceled, to Reappear As 4-5 RFPs

January 15, 1982

Staff Advisory Boards To Be Formed; Three BSCs Proposed

August 11, 1995

FDA Grants Orphan Designation To Photofrin for Mesothelioma

December 30, 2011

Three Scientists Win Albert Lasker Medial Research Awards

September 30, 1994